The Hyderabad-based pharmaceutical giant, which operates across 100 countries with a dominant presence in API manufacturing, has witnessed its stock surge 49.64% over the past year, significantly outperforming the Sensex which declined 2.74% during the same period. Trading at ₹10,305.00 as of November 6, 2026, the stock has gained 1.53% in the latest session, reflecting strong investor confidence following the stellar quarterly performance.